At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 33 enrolled
Drug / intervention
Raltegravir +1 moredrug
Likely dose
Raltegravir 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3b, Single Arm, Single Site Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Clinical Trial (NCT02284035)
In Brief
A Phase 3 clinical trial evaluating Raltegravir and Lamivudine for HIV Infections and 2 related conditions. Completed, enrolled 33 participants across 1 site.
Detailed Summary
Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of Lamivudine (150 mg BID) plus Raltegravir (400 mg BID) switching to Lamivudine (300 mg QD) plus Raltegravir (1200 mg QD): Roll-over study of the RALAM clinical trial (NCT02284035)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, HIV-1-infection, HIV Seropositivity
CountriesSpain
CollaboratorsFundacion Clinic per a la Recerca Biomédica
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartMay 2018
Primary CompletionMar 2021
Study CompletionNov 2022
TodayJul 2026
First PostedOct 17, 2017
Enrollment StartMay 2, 2018
Primary CompletionMar 30, 2021
Study CompletionNov 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 8.7 years ago
Interventions
Raltegravirdrug
Raltegravir (1200 mg QD)
Lamivudinedrug
Lamivudine (300 mg QD)